TB-500 vs PRP vs Cortisone: How the Evidence Actually Compares

How Do TB-500, PRP, and Cortisone Compare?

These three are not comparable interventions, and the most useful thing to understand is why. Cortisone is an approved anti-inflammatory drug with decades of human trials — it reliably reduces pain short-term, and in tendon conditions the same trials show worse outcomes at 6 to 12 months than doing far less. PRP is an autologous blood preparation with a large but genuinely conflicting human trial record, undermined by the fact that "PRP" describes dozens of different preparations rather than one intervention. TB-500 has no controlled human trials for any musculoskeletal condition at all.

So the honest comparison is not "which works best." It is that two of these have been tested in humans and produced complicated answers, and the third has not been tested in humans. That difference in evidence class matters more than any mechanism.

> Research disclaimer: This article compares published evidence for informational and research purposes only. TB-500 is sold as a research chemical and is not for human consumption. Nothing here is medical advice or a treatment recommendation. Cortisone and PRP are clinical procedures administered by licensed clinicians, and decisions about them belong in a conversation with a qualified physician who can examine the actual injury.

What Does Each One Actually Do?

They act through entirely different biology, which is why "which is better" tends to be the wrong question.

Cortisone (corticosteroid) is a potent suppressor of inflammation. It works by broadly downregulating inflammatory gene expression. Crucially, it does not repair tissue — it quiets the inflammatory response. In tendon tissue it is actively catabolic, meaning it can degrade the collagen matrix it is injected near. Pain relief and tissue healing are not the same thing, and cortisone delivers the first while potentially working against the second.

PRP (platelet-rich plasma) is made by drawing the patient's own blood, centrifuging it to concentrate platelets, and injecting that concentrate into the injured tissue. Platelets release a mix of growth factors — PDGF, TGF-β, VEGF, and others — and the theory is that delivering them at concentration stimulates a repair response. It is an attempt to amplify healing rather than suppress inflammation.

TB-500 is a synthetic peptide related to Thymosin Beta-4. Its characterized activity is binding G-actin and regulating actin dynamics, which governs cell migration, with downstream effects studied on angiogenesis. Our mechanism of action article covers this in depth, and our anti-inflammatory research overview addresses its inflammation-related effects, which are modulatory rather than suppressive like a steroid.

What Do Human Trials Show for Cortisone?

Cortisone has the deepest human evidence base of the three, and the results are more nuanced than its popularity suggests.

For tendinopathy, particularly lateral epicondylitis (tennis elbow), randomized trials and meta-analyses have produced a consistent and somewhat uncomfortable pattern: corticosteroid injection produces clear short-term pain relief measured at around 6 weeks, but at 6 to 12 months the injected groups fare worse than placebo, physiotherapy, or a wait-and-see approach, with higher recurrence rates. The short-term benefit is real; so is the longer-term penalty.

For knee osteoarthritis, the picture around repeated injections is also cautionary. Trial evidence has raised concerns that repeated intra-articular corticosteroid injections over a period of years may be associated with cartilage volume loss without delivering meaningful pain benefit over saline.

Known risks are well documented and include tendon weakening and rupture — the reason clinicians are wary of injecting near the Achilles — along with skin and subcutaneous fat atrophy, local depigmentation, and transient blood glucose elevation.

None of this makes cortisone useless. It has real value where breaking a pain cycle enables rehabilitation, or in inflammatory conditions where suppressing inflammation is the actual goal. But it earns that role by having been tested thoroughly enough for its limitations to be known.

What Do Human Trials Show for PRP?

PRP has been studied extensively in humans, and the honest summary is conflicted.

The single biggest problem is that PRP is not one thing. Preparations differ in platelet concentration, whether leukocytes are included (leukocyte-rich versus leukocyte-poor), whether platelets are activated before injection, the centrifugation protocol, and the injection volume and frequency. Two studies both labeled "PRP" may have tested substantially different biological products. This heterogeneity makes pooling results across trials genuinely difficult and plausibly explains much of the inconsistency in the literature.

Within that limitation:

Knee osteoarthritis is where PRP's evidence is most developed, and it remains contested. Some randomized trials and meta-analyses report benefit over hyaluronic acid or saline; other well-conducted trials have found PRP no better than saline injection. The disagreement is not resolved.

Lateral epicondylitis shows mixed results, with some trials favoring PRP over corticosteroid at longer follow-up — consistent with the observation that cortisone's comparative disadvantage grows over time.

Rotator cuff and Achilles tendinopathy evidence is weaker and largely unconvincing. See our rotator cuff research and tendon repair overviews for the parallel TB-500 discussion.

Practically, PRP is autologous, which gives it a favorable safety profile — the main risks are procedural, such as injection-site pain and infection risk. It is generally not covered by insurance and is paid out of pocket. It is also permitted under WADA rules, having been removed from the Prohibited List in 2011.

What Do Human Trials Show for TB-500?

There are none.

This is the entire answer, and it deserves to be stated plainly rather than softened. There are no controlled human trials of TB-500 for tendinopathy, osteoarthritis, ligament injury, muscle strain, or any other musculoskeletal condition. There is no established human dosing, no efficacy data, no controlled safety data, and no long-term follow-up in humans.

What exists is mechanistic research on Thymosin Beta-4 — cell-culture and animal work on actin regulation, cell migration, angiogenesis, and wound healing. That research is legitimate and genuinely interesting. It is simply not the same category of evidence as a randomized controlled trial in people, and the gap between the two is where most peptide marketing lives.

Additional distinctions that matter:

Regulatory status. Cortisone is an approved drug. PRP is a procedure using the patient's own blood. TB-500 is a research chemical sold explicitly not for human consumption, with no approval for any indication. See our legal status overview.

Product identity. With cortisone, a pharmacy dispenses a known compound at a known concentration. With PRP, the input is the patient's own blood. With TB-500, the contents of the vial depend entirely on an unregulated supplier's quality control — and as covered in our fragment 17-23 guide, even the sequence sold under the name varies.

Anti-doping. PRP is permitted. TB-500 is prohibited at all times under WADA's peptide hormones and growth factors category — a decisive consideration for tested athletes, as covered in our drug testing research.

Who administers it. The first two involve a clinician who examines the injury and can identify when the diagnosis is wrong.

How Should a Researcher Read This Comparison?

The framing that gets people into trouble is treating these as three items on a menu, ranked by potency. They differ in kind.

A useful way to hold it:

| | Cortisone | PRP | TB-500 |
|---|---|---|---|
| Human RCT evidence | Extensive | Extensive but conflicting | None |
| What it does | Suppresses inflammation | Delivers concentrated growth factors | Studied for actin regulation and angiogenesis |
| Effect on tissue repair | Catabolic in tendon | Theoretically anabolic; contested | Unknown in humans |
| Known risks | Well documented | Mainly procedural | Not characterized in humans |
| Regulatory status | Approved drug | Autologous procedure | Research chemical, not for human use |
| WADA status | Route-dependent restrictions | Permitted | Prohibited at all times |
| Product consistency | Standardized | Varies by protocol | Varies by supplier |

The pattern worth noticing: the more thoroughly something has been tested, the more modest and qualified its claims become. Cortisone has been studied enough that we know exactly where it disappoints. PRP has been studied enough for its inconsistency to be visible. TB-500's claims sound cleaner than either — and that cleanliness is a function of absent data, not superior performance. Unstudied compounds always have the best-sounding stories, because nothing has yet contradicted them.

For anyone with an actual injury, the more decision-relevant fact is usually that the strongest evidence in tendinopathy and osteoarthritis generally supports progressive loading and structured rehabilitation rather than any injection. That is unglamorous, and it is what the trial literature keeps returning. General safety considerations for TB-500 specifically are covered in our side effects and safety overview.

Frequently Asked Questions

Is TB-500 better than PRP?

There is no evidence to support that claim, because the comparison has never been made. No study has tested TB-500 against PRP in humans, and TB-500 has no controlled human trials for any musculoskeletal condition. PRP has an extensive if conflicting human trial record. Claiming one is better than the other requires comparative data that does not exist.

Is TB-500 better than cortisone for tendon injuries?

This has not been studied, so it cannot be answered from evidence. It is worth noting that cortisone's own record in tendinopathy is unflattering — trials consistently show short-term pain relief but worse outcomes at 6 to 12 months than placebo or physiotherapy, and it is catabolic to tendon tissue. Performing poorly against a comparator with known long-term drawbacks would still be a meaningful finding, but no trial has tested TB-500 to establish even that.

Why is PRP allowed in sports but TB-500 is banned?

PRP was removed from the WADA Prohibited List in 2011 and is currently permitted. It uses the athlete's own blood components rather than introducing an exogenous substance. TB-500 falls under WADA's category for peptide hormones, growth factors, and related substances, which is prohibited at all times, both in and out of competition. Using it constitutes an anti-doping rule violation for any athlete subject to testing.

Does cortisone actually heal injuries?

No. Cortisone suppresses inflammation and reduces pain, but it does not repair tissue, and in tendon it is catabolic to the collagen matrix. Its legitimate value lies in reducing pain enough to enable rehabilitation, or in treating conditions where inflammation itself is the problem. Pain relief and tissue healing are distinct outcomes, and conflating them is a common source of confusion about what a cortisone injection accomplishes.

Why does PRP research disagree with itself so much?

Largely because PRP is not a single standardized intervention. Preparations vary in platelet concentration, leukocyte content, whether platelets are activated, centrifugation protocol, and injection volume and frequency. Two trials both described as testing PRP may have used substantially different biological products, which makes pooling results across studies difficult and plausibly accounts for much of the inconsistency in the published record.

Sourcing Quality Research Peptides

For laboratory research applications, compound identity and purity are essential — analytical work is only meaningful when the vial actually contains the labeled peptide at the stated purity. Look for vendors that publish third-party testing and certificates of analysis with HPLC purity above 98%. Apollo Peptide Sciences provides independent third-party testing and full COAs on its TB-500, which matters whenever your research depends on knowing exactly what is in the vial.